BioPharma Dive May 12, 2026 Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
BioPharma Dive May 12, 2026 A year after Vertex’s big launch, pain drug research faces a pivotal moment
BioPharma Dive May 11, 2026 Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
BioPharma Dive May 11, 2026 Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
BioPharma Dive May 8, 2026 FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
BioPharma Dive May 7, 2026 Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B